RankAlpha logo
Back to Rankings

CRSP

CRISPR TherapeuticsB
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
Bull assumes successful pivotal readouts, timely approvals, and early commercial traction that expand revenue and justify premium multiples.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +10.2.
What can break
Competitive advances compressing addressable market
Momentum
22
Value
41
Sentiment
96
Setup hits (3d)
— · Net —
AI TargetsBase $69.00 · Bull $120.00 · Bear $35.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-23 • Model: RankAlpha Sentiment AI
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net —
Target $82.15
Why
Momentum22 · Δ7d -16.6
Value41 · Δ7d -0.1
Sentiment96 · Δ7d +10.2
So what
Strength-led posture. Favor watchlist adds and disciplined entries.
Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits
Lead driver: Sentiment · See AI snapshot
Momentum
22
26% active weight
Current posture
7d trendSoftening
Δ7d
-16.6
Δ21d
-26.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
96
34% active weight
Current posture
7d trendImproving
Δ7d
+10.2
Δ21d
+17.1
Why this grade

Composite grade B. Momentum 21.8 / Value 41.1 / Sentiment 96.4

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$4.61B
Beta
1.72
Shares Out
96.45M
P/E (TTM) · Derived
-7.4
P/S (TTM)
137.09
P/FCF (TTM) · Derived
-10.98
Rev YoY
+68.6%
EPS YoY
-19.1%
Gross Margin
-5283.4%
Op Margin
-1498.3%
Net Debt
-$1.78B
Current Ratio
17.96
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology